Patient Centric Healthcare App Market Future Horizons: Unlocking Potential

Patient-centric healthcare apps have revolutionized the healthcare industry by providing convenient, cost-effective, and quality healthcare services to patients. These apps enable patients to manage and track their health records, book appointments, order prescriptions, and access educational healthcare resources from the comfort of their homes. With features like remote patient monitoring and quick symptom checkers, patient centric healthcare apps have streamlined the process of diagnosis and treatment. The global Patient Centric Healthcare App Market is estimated to be valued at US$ 9,760.4 Mn in 2023 and is expected to exhibit a CAGR of 39.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Increasing adoption of technology in patient care services has emerged as a key trend fueling the growth of the patient centric healthcare app market. Healthcare providers are increasingly embracing digital tools and solutions to enhance patient engagement and streamline workflow. Patient centric apps provide a convenient platform for remote monitoring of patients with chronic conditions, thereby reducing hospital visits and healthcare costs. They also enable patients to access educational resources and consultation with healthcare professionals from anywhere. This has boosted adoption of such apps amid the ongoing crisis by facilitating virtual healthcare delivery. Growing preference for personalized care and focus on patient-provider communication is expected to further propel the demand over the forecast period.

Segment Analysis

The global patient centric healthcare app market can be segmented based on products, end-users and regions. Based on products, the market is segmented into wellness management and health condition management apps. The wellness management apps segment dominates the market as these apps help individuals to manage their fitness, diet and health goals effectively and track fitness activities like steps count. They provide wellness solutions like weight loss programs and preventive care which are increasingly being used by the health-conscious population.

Key Takeaways

The global patient centric healthcare app market is expected to witness high growth during the forecast period of 2023 to 2030. The market is estimated to reach a value of US$ 9,760.4 Mn by 2023 and projected to grow at a CAGR of 39.% between 2023 and 2030.

Regional analysis

North America dominates the global market currently due to growing adoption of advanced healthcare technologies and presence of major players in the region. However, Asia Pacific region is expected to witness the fastest growth over the forecast period supported by rising awareness regarding telehealth and increasing penetration of smartphones in emerging economies like China and India.

Key players

Key players operating in the patient centric healthcare app market are Bayer AG, Novartis AG, Siemens Healthineers AG, Pfizer Inc., Koninklijke Philips NV, MobileSmith Inc., Merck KgaA, MFine Pvt Ltd., Athenahealth Inc., Oracle (Cerner Corporation), ASSURECARE LLC (IPATIENT CARE), Boston Scientific Corporation, International Business Machines Corporation (IBM), Allscripts Healthcare Solutions Inc., and Baxter International Inc. (HillRom Services, Inc.).

Neurofibromatosis Treatment Drugs Market Trends: Navigating Future Therapeutics

 Neurofibromatosis is a genetic disorder that causes tumors to form on nerve tissues. Neurofibromatosis treatment drugs are used to slow or stop tumor growth. The drugs are available in different delivery methods like oral and injectable, to provide convenience to patients. The global Neurofibromatosis Treatment Drugs Market is estimated to be valued at US$ 5,759.6 Mn in 2023 and is expected to exhibit a CAGR of 24% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Emerging innovative drugs delivery methods are expected to drive the neurofibromatosis treatment drugs market growth over the forecast period. Various pharmaceutical companies are developing novel delivery systems to offer better efficacy and patient compliance. For example, some players are developing long-acting injectable drugs that remain effective in the body for several weeks or months with a single dose. This reduces treatment frequency and provides comfort to patients. Similarly, research is ongoing on development of transdermal drug delivery systems and implantable drug delivery devices that can release drugs continuously over a prolonged period. Such advances are anticipated to bolster the demand for neurofibromatosis treatment drugs in the coming years.

Segment Analysis

The global neurofibromatosis treatment drugs market can be segmented based on type, drug class and distribution channel. By type, the pseudopolyposis syndrome segment dominates the market as it causes intestinal polyps or non-cancerous (benign) growths in the digestive tract which leads to abdominal pain, bleeding, and changes in bowel habits, if left untreated. By drug class, the fms-like tyrosine kinase 3 inhibitors segment holds the largest share as Drugs like sunitinib and sorafenib, which inhibits multiple receptor tyrosine kinases including fms-like tyrosine kinase 3 (FLT3), have demonstrated promising results in clinical studies.

Key Takeaways

Regional analysis

The neurofibromatosis treatment drugs market in North America is expected to maintain its dominance during the forecast period. This is majorly due to the growing prevalence of neurofibromatosis in the region coupled with rising healthcare expenditure. According to Children's Tumor Foundation, neurofibromatosis affects approximately 1 in every 2,000–3,000 individuals in North America. Europe Neurofibromatosis treatments market is also anticipated to grow at a considerable rate owing to the availability of advanced treatment options and growing initiatives by government organizations to spread awareness regarding neurofibromatosis.

Key players

Key players operating in the neurofibromatosis treatment drugs market are BIO-key International, Fujitsu Limited., 3M Cogent, Inc., MorphoTrust, Imprivata, Inc., Crossmatch Technologies, Inc., Toshiba Medical System Corporation, NEC Corporation, Hitachi Ltd., Integrated Biometrics, and Qualcomm Technologies, Inc. These players are focusing on development of advanced technologies for effective management of neurofibromatosis symptoms. For instance, in 2019, BIO-key filed for pre-market approval of their flagship biometric technology, PortalGuard with the U.S. Food and Drug Administration to facilitate positive patient identification in healthcare settings.

Medical Imaging Reagents Market Unraveled: Understanding Market Dynamics

 

Medical imaging reagents are used in diagnostic applications such as MRI, ultrasound, X-ray, and nuclear imaging for advanced diagnostics and visualization of organs, soft tissues, and bone structures. Advancements in molecular imaging reagents and targeted contrast agents enable to image biological processes at the cellular and molecular levels with high sensitivity and specificity. The global Medical Imaging Reagents Market is estimated to be valued at US$ 11.21 Billion in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

Advancing innovation in molecular imaging reagents to boost the market growth over the forecast period. Molecular imaging allows for personalized medical imaging at cellular and molecular levels with high sensitivity and specificity. Ongoing R&D in molecular imaging reagents, targeted contrast agents, and specialty reagents for advanced applications like nucleic acid, and protein targeted probes. These advancements enable ultrasensitive detection of molecular changes at early disease stages and help monitor therapeutic responses in real-time. Leading players are focusing on developing novel targeted molecular imaging agents for applications in oncology, cardiology, neurology, and other areas which is expected to drive the medical imaging reagents market growth during the forecast period.

Segment Analysis

The global medical imaging reagents market is segmented based on product, application, end user, and region. On the basis of product, contrast media accounts for the largest share in the medical imaging reagents market. Contrast media enhances the visibility of internal body structures during imaging procedures like CT, MRI, ultrasound and X-ray scans. High usage of contrast media for diagnostic purposes across various disease areas such as oncology, cardiology and neurology is driving the growth of this segment.

Key Takeaways

The global Medical Imaging Reagents market is expected to witness high growth. The region of North America dominated the market and is expected to continue its dominance during the forecast period. This can be attributed to well-established healthcare facilities, technological advancements in medical imaging modalities and growing prevalence of chronic diseases.

Key players operating in the Medical Imaging Reagents market are Bayer AG, Bracco SpA, Eli Lilly and Company, General Electric Company (GE Healthcare), among others. Bayer AG offers a comprehensive portfolio of contrast agents, including Xenetix and Gadovist, among others. The company focuses on research and development activities to develop innovative contrast agents.

Europe is also expected to hold a significant share in the market. Presence of major players, favorable reimbursement policies, and government support for research & development drives the growth of the European medical imaging reagents market.

Asia Pacific region is poised to exhibit the highest CAGR during the forecast period. Increasing healthcare expenditure, rising incidences of chronic diseases, growing awareness about diseases diagnosis are factors fueling the market growth in this region.

Light Therapy Market Overview: Shaping the Future of Phototherapy

 

The light therapy market involves products that emit specific wavelengths of light to effectively treat various skin conditions, improve mood, and reduce pain. Light therapy devices help improve acne, psoriasis, eczema, and other inflammatory skin conditions by altering cell behavior and stimulating the skin. They offer non-invasive pain relief and are proven effective for treating mild to moderate depression during winter when sunlight is limited.

The global light therapy market is estimated to be valued at US$ 989.2 Mn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The growing popularity of light therapy to treat various skin conditions has been a major driver of market growth. Light therapy has gained acceptance as an effective treatment alternative to pharmaceuticals for certain inflammatory skin issues and mood disorders. It offers side effect-free treatment compared to long-term use of topical steroids or oral medications. Rising consumer preference for non-invasive aesthetic procedures has further increased the demand for light therapy products in skin rejuvenation treatments. Manufacturers are focusing on continuous technology advancements such as launching devices with customized light settings and wide panels for faster treatment sessions. This makes light therapy more convenient and accessible to consumers.

Segment Analysis
The global light therapy market is dominated by the Homecare devices sub-segment, which accounts for over 50% share of the overall market. This is because light therapy equipment is expensive and homecare devices provide convenience and flexibility for patients to use the devices as per their comfort. The rising awareness regarding the benefits of light therapy for various medical conditions and self-treatment of minor mood issues at home is driving the demand for homecare devices for light therapy.

Key Takeaways
The global light therapy market is expected to witness high growth over the forecast period of 2023 to 2030, driven by the rising prevalence of Seasonal Affective Disorder (SAD) and other mental disorders. The global light therapy market is estimated to be valued at US$ 989.2 Mn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030.

Regional analysis
Europe dominates the global market and accounted for over 35% share in 2023 owing to the high awareness levels regarding mental health issues and greater medical access in countries like Germany, UK, and France. However, Asia Pacific is expected to register the fastest CAGR during the forecast period due to the rising geriatric population suffering from neurological disorders in countries like China and Japan.

Key players
Koninklijke Philips N.V., Verilux, Inc., and Northern Light Technology are some of the leading players in the global light therapy market. Koninklijke Philips N.V. offers a wide range of light therapy devices for medical professionals as well as individual consumers through both offline and online channels. Verilux, Inc. specializes in the development and marketing of full-spectrum light therapy lamps for alleviating Seasonal Affective Disorder.

Herbal Medicinal Products Market Trends: Rising Demand for Botanical Therapies

 

The herbal medicinal products market consists of organic herbs and plants utilized for medicinal purposes. Herbal medicines are in high demand due to their natural compositions and negligible side effects. Applications include treatment of cold, cough, diarrhea, indigestion, skin diseases, and others. The global herbal medicinal products market is estimated to be valued at US$ 199.07 Bn in 2023 and is expected to exhibit a CAGR of 7.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key drivers augmenting the herbal medicinal products market growth is the rising awareness among consumers regarding fitness, health, and well-being. There is a preference shift towards healthy dietary and lifestyle choices, which pulls the demand for organic and natural herbal formulations. Herbal medicines are deemed safe with no severe side effects. Its usage for preventive healthcare has become popular among millennials. Consumer education about traditional uses of medicinal plants is further fueling consumption. Advances in extraction techniques by manufacturers are harnessing phytochemicals with curative properties efficiently.

Segment Analysis
The global herbal medicinal products market is segmented on the basis of product and application. Based on product, the market is segmented into ayurvedic medicinal products, Chinese medicinal products, homeopathic medicinal products, and others. The ayurvedic medicinal products segment dominates other segments as India has a huge consumer base that prefers Ayurveda products for various diseases and medical conditions. Ayurvedic medicine focuses on prevention rather than treatment by following various lifestyle practices.

Key Takeaways
The global herbal medicinal products market is expected to witness high growth. The market is estimated to reach a value of US$ 379.34 Bn by 2030 from US$ 199.07 Bn in 2023, expanding at a CAGR of 7.7% during the forecast period.

Regional analysis related content comprises
The Asia Pacific region holds the highest share in the global herbal medicinal products market. India and China have a huge consumer base that prefers herbal medicine over chemical drugs. These countries have also created a strong distribution and supply chain system for various herbal extracts and final herbal medicinal products. Moreover, herbs and herbal extracts play a huge role in traditional Chinese medicine and Ayurveda.

Key players related content comprises
Key players operating in the herbal medicinal products market are Blackmores Limited, Sanofi-Aventis Healthcare PTY Ltd., Arkopharma SA, Nutraceutical Corporation, STADA Arzneimittel AG, Himalaya Global Holdings Ltd, Integria Healthcare, Boiron Group, Young Living Essential Oils, Mountain Rose Herbs. Blackmores Limited specializes in the development, manufacturing, marketing, and distribution of herbal and vitamin supplements. It has a wide product portfolio and global distribution network.

Healthcare BPO Market Insights: Key Players and Strategies

 

Healthcare BPO refers to outsourcing non-core healthcare services like revenue cycle management, medical billing & coding, medical document transcription and other healthcare administrative functions. This allows healthcare providers to focus on patient care while leveraging the expertise of specialized players. The growing demand for these services is driven by the need to optimize healthcare costs and workflows.

The global Healthcare BPO Market is estimated to be valued at US$ 10.19 billion in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Technology-driven Growth
The healthcare BPO market is witnessing heavy investments in digitization and automation technologies like cloud computing, AI and blockchain. This is helping players streamline operations, improve quality and turnaround times. Machine learning based tools are enabling more accurate and efficient medical coding, billing and claims management. Automated transcription and translation solutions are further boosting productivity. The rapid adoption of these technologies is expected to drive the healthcare BPO market growth at an accelerated pace over the forecast period.

Segment Analysis
The global healthcare BPO market is divided into payer, provider, and pharmaceutical segments. The payer segment is expected to dominate the market during the forecast period. Factors such as cost reduction pressure on insurance companies and the need to improve operational efficiency are driving the growth of this segment. Payer organizations handle numerous administrative tasks including claims processing, customer interaction services, and fraud detection. Outsourcing such back-office operations helps them focus on core competencies.

Key Takeaways
The global healthcare BPO market is expected to witness high growth during 2023-2030. The market size is projected to grow from $10.19 billion in 2023 to $18.73 billion by 2030, registering a CAGR of 6.1% during the forecast period.

Regional analysis
North America region is expected to remain the largest and fastest growing regional market for healthcare BPO during the forecast period. Significant presence of leading BPO service providers and favorable government regulations are promoting outsourcing in this region. Asia Pacific region is also emerging as a major outsourcing hub and is expected to register the highest CAGR during the forecast period. Countries such as India offer strategic advantages including skilled labor pool and competitive costs.

Key players
Key players operating in the healthcare BPO market include Companies are focusing on development of technologically advanced products to hold the largest share in the healthcare BPO market. The company provides services such as revenue cycle management, medical billing/coding, medical record coding, claims processing, and transaction processing.

Exploring Global Guidewires Market Dynamics and Trends

Guidewires are medical devices that aid physicians in performing minimally invasive surgeries and diagnostic procedures. Guidewires allow insertion of other medical devices like catheters, biopsy forceps, and stents inside blood vessels, veins and arteries. They help physicians navigate narrow, twisted, and hard to reach areas of the body with precision. The rising prevalence of cardiovascular disorders has increased the demand for minimally invasive surgeries and procedures which require guidewires. The global Guidewires Market is estimated to be valued at US$ 8.1 Bn in 2023 and is expected to exhibit a CAGR of 4.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The rising prevalence of cardiovascular disorders has accelerated the growth of the Guidewires Market. Cardiovascular diseases, especially heart diseases and stroke, are the leading causes of deaths globally. According to World Health Organization (WHO), cardiovascular diseases account for over 17.9 million deaths per year which is expected to grow to over 23.6 million by 2030. Increasing risk factors such as sedentary lifestyle, unhealthy diet and smoking have contributed significantly to the growing incidence of cardiovascular diseases. As guidewires are extensively used in minimally invasive cardiological procedures such as cardiac catheterization and angioplasty, the rising disease burden has augmented the demand for guidewires and subsequent market growth over the forecast period.

Segment Analysis
The global guidewires market is dominated by coronary guidewires sub segment. Coronary guidewires accounted for the largest share of the market owing to increasing incidence of cardiovascular diseases and rising number of PCI procedures globally. These guidewires are primarily used in angioplasty and other cardiovascular treatments procedures.

Key Takeaways
The global guidewires market is expected to witness high growth over the forecast period of 2023 to 2030. Factors such as increasing aging population, growing prevalence of lifestyle diseases and technological advancements will drive the market growth.

Regional analysis
North America currently dominates the guidewires market led by the United States owing to high incidence of cardiac diseases and growing number of surgical procedures in the region. Growing healthcare expenditure and robust medical infrastructure further support market growth in North America.

Key players
Key players operating in the guidewires market are Boston Scientific Corporation, ASAHI INTECC Inc., Cordis Corporation . Boston Scientific Corporation is the leading player in the guidewires market with wide product portfolio and global presence. Cordis Corporation holds a significant share in guidewires market especially in coronary guidewires segment.

Electrosurgical Devices Market Growth: Energizing Surgical Procedures

 

Electrosurgical devices use high-frequency alternating electric current to cut, coagulate, desiccate and fulgurate tissue. These devices offer advantages like reduced blood loss during surgery, minimal damage to surrounding tissue and decreased surgical and recovery time over conventional surgery. The global electrosurgical devices market is estimated to be valued at US$ 6,892.4 Mn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends: Advancements in electrosurgical devices technologies is one of the major trends fueling the growth of this market. Manufacturers are focusing on developing electrosurgical devices integrated with advanced technologies like bipolar technology, monopolar technology and cutting & coagulation modes for improved precision, speed and control during surgical procedures. For instance, in 2021, Olympus Corp. launched the Thunderbeat electrosurgical device integrated with advanced bipolar and monopolar technologies for minimally invasive surgeries. The new technologies in these devices allow surgeons to use various energy modalities and achieve more accurate and controlled tissue effects. This increases the efficiency of surgical procedures and leads to better clinical outcomes.

Segment Analysis
The global electrosurgical devices market is dominated by electrosurgical generators sub segment. Electrosurgical generators generate radio frequency electrical current and are used to cut, coagulate, desiccate and fulgurate tissues. They provide necessary power to operate electrosurgery instruments like electrosurgical generators, electrosurgery electrodes, bipolar forceps and monopolar probes. These generators help to perform minimally invasive surgeries in the field of gynecology, urology, gastroenterology, dermatology and general surgery. Their widespread adoption across ambulatory surgical centers and hospitals drive the growth of this sub segment.

Key Takeaways
The global electrosurgical devices market is expected to witness high growth during the forecast period from 2023 to 2030. The market size is projected to reach US$ 6,892.4 Mn by 2023 from US$ 4,256.2 Mn in 2018, at a CAGR of 6.8%.

Regional analysis
North America dominated the global market in 2018 and is anticipated to maintain its dominance during the forecast period. Higher healthcare spending, strong presence of industry players, growing disease prevalence and increasing initiatives for minimally invasive procedures are some factors boosting the growth of electrosurgical devices market in North America.

Key players
Key players operating in the electrosurgical devices market are Bovie Medical Corporation, Medtronic Plc, BOWA-Electronic GmbH & Co. KG, KLS Martin, B. Braun Melsungen AG, Conmed, Olympus Corp., Boston Scientific Corporation, Erbe Elektromedizin GmbH, Symmetry Surgical Inc., Encision Inc., Gala Therapeutics, Inc., Apyx Medical Corporation, and Johnson & Johnson Services, Inc. Bovie Medical Corporation and Medtronic Plc hold majority market share due to their robust product portfolio and global presence.

Blood Collection Devices Market Trends: Advancing Vascular Access

 

Blood collection devices play a vital role in diagnosing various illnesses and diseases by allowing healthcare providers to safely collect and transport blood samples for laboratory testing. Advances in materials, design, and automation have led to the development of novel blood collection technologies such as safety-engineered sharps that prevent needlestick injuries and closed collection systems that minimize user contact with needles and blood samples. These innovations help ensure optimal sample quality while protecting healthcare workers from exposure to infectious agents. The global Blood Collection Devices Market is estimated to be valued at US$ 9,244.72 Mn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The adoption of advanced blood collection technologies is expected to significantly drive market growth over the forecast period. Continuous investments by major players to develop innovative safety devices such as needlestick prevention technology and closed blood collection systems that minimize contamination risks and ensure sample integrity are increasing the uptake of advanced blood collection products among healthcare facilities. Additionally, high demand for safe blood collection practices from healthcare professionals due to the ongoing COVID-19 pandemic is boosting the demand for advanced safety-engineered devices. Rising awareness about the benefits of advanced blood collection solutions for accurate diagnosis and infection control is anticipated to further augment the demand.

Segment Analysis
The global blood collection devices market is segmented into needles & syringes, blood collection tubes, blood bags, lancets, and others. Amongst these, the needles & syringes segment currently dominates the market owing to increasing prevalence of chronic and infectious diseases. This segment is expected to continue its dominance during the forecast period due to rising number of surgical procedures that require blood collection through intravenous route.

Key Takeaways
The global blood collection devices market is expected to witness high growth during the forecast period of 2023 to 2030. It is projected to grow at a CAGR of 6.1% during this period. By 2030, the market size is anticipated to reach US$ 15,256.98 Mn.

Regional analysis
North America currently dominates the global blood collection devices market. The major factors driving the market growth in the region include growing burden of chronic diseases, expanding geriatric population, rising number of blood donations and transfusion procedures. Asia Pacific is expected to be the fastest growing market during the forecast period owing to increasing healthcare spending, growing medical tourism, rising awareness about blood donation.

Key players
Key players operating in the blood collection devices market include Becton Dickinson and Co, Terumo Corp, Cardinal Health Inc, SARSTEDT AG & Co KG, Nipro Corp, Thermo Fisher Scientific Inc, Sekisui Chemical Co Ltd, Greiner Bio-One International GmbH, FL Medical SRL, and IntervacTechnology OU. Becton Dickinson and Co currently leads the market share followed by Terumo Corp owing to their robust product portfolio and widespread geographic presence across major markets.

Anti-Neprilysin Market Analysis: Evolving Renal Health Dynamics

 The global Anti-Neprilysin Market caters to the growing need for efficient treatment of various renal and cardiovascular diseases. Anti-Neprilysin drugs have proven effective in attenuating proteinuria and slowing the progression of chronic kidney diseases. The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The substantial rise in the incidence of chronic kidney diseases across the world represents a key growth driver for the anti-Neprilysin market. Neprilysin inhibitors have emerged as a viable therapeutic approach for preventing kidney damage in various renal conditions. Ongoing clinical trials are evaluating the efficacy of anti-Neprilysin drugs such as sacubitril/valsartan in delaying kidney function decline in patients with diabetes and hypertension. Moreover, favorable regulatory framework for novel neprilysin inhibitor therapies is encouraging pharmaceutical research on this class of drugs.
Segment Analysis

The global Anti-Neprilysin market is dominated by the combination drugs sub segment. This is because combination drugs such as Sacubitril/Valsartan act synergistically by blocking both neprilysin and Angiotensin receptors, allowing for better management of conditions like heart failure. Sacubitril/Valsartan is the first approved neprilysin inhibitor for use in heart failure patients.

Key Takeaways

The global Anti-Neprilysin market is expected to witness high growth over the forecast period of 2023 to 2030. Rising prevalence of heart failure and related comorbidities globally will drive demand for neprilysin inhibiting drugs.

Regional analysis

North America currently dominates the global Anti-Neprilysin market owing to availability of advanced treatments, favorable reimbursement policies, and high awareness levels regarding neprilysin inhibiting drugs. The US holds the largest share in the regional market led by presence of major players and frequent FDA approvals. Asia Pacific is expected to witness fastest growth during the forecast period with China and India emerging as high potential markets. This can be attributed to increasing healthcare spending, growing geriatric population, and rising incidence of cardiovascular diseases.

Key players

Key players operating in the Anti-Neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd. BIOPROJET and Novartis AG currently dominate the market with their blockbuster drug Sacubitril/Valsartan (trade name: Entresto). Pharmaleads SA is developing novel neprilysin inhibitors with improved safety profiles. Theravance Biopharm is engaged in research on next generation neprilysin inhibiting drugs for various conditions. Cipla Inc and Oceanic Pharmachem Pvt. Ltd focus on generics of Sacubitril/Valsartan.

Steam Inhaler Devices Market Growth: Transforming Inhalation Therapies

 

Market Overview:

Steam inhaler devices allow users to inhale steam to help relieve symptoms associated with colds, sinus infections, allergies and other congestion problems. It helps thin out mucus in the nasal passages, sinuses and lungs, making it easier for patients to breathe.

The global Steam Inhaler Devices Market is estimated to be valued at US$ 6,721.4 Mn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the key trends in the steam inhaler devices market is the increasing adoption of digital therapeutics. Digital therapeutics involve the integration of digital technologies with evidence-based therapeutic interventions for disease prevention, diagnosis, treatment, monitoring and management. Companies are increasingly launching steam inhaler devices that are integrated with mobile applications and digital platforms which help users track treatment progress, monitor symptoms and receive personalized treatment recommendations. For instance, Vicks launched its Vicks portable steam vaporizer connected to the Ear Pick app which allows users to monitor symptoms, track treatments and receive customized guidance for asthma, colds and cough relief.

Segment Analysis

The global steam inhaler devices market is segmented into portable steam inhalers and desktop steam inhalers. The portable steam inhalers segment dominated the market in 2022 and is expected to continue its dominance over the forecast period. Portable steam inhalers offer mobility and ease of use which makes them a preferred choice among consumers. Their compact size allows users to carry them anywhere.

Key Takeaways

The global steam inhaler devices market is expected to witness high growth, exhibiting CAGR of 7.9% over the forecast period, due to increasing prevalence of respiratory diseases.

Regional analysis

North America dominated the global market in 2022 and is expected to maintain its dominance during the forecast period. Higher awareness regarding steam inhalation therapy and growing respiratory disease burden in the US and Canada drives the market in the region. Asia Pacific is expected to witness fastest growth over the forecast period owing to rising geriatric population, increasing healthcare expenditure and growing pollution levels in major countries like India and China.

Key players

Key players operating in the steam inhaler devices market are Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Perrigo Company plc, Taro Pharmaceutical Industries Ltd., Provectus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Mylan N.V.. Merck & Co., Inc. offers Nasonex allergy spray which is used for relief of symptoms from seasonal allergic rhinitis/hay fever.

Patient Recliners Market Analysis: Evolution of Patient-Centric Furniture

 Patient recliners are medical recliners used in healthcare facilities for seating and supporting patients and elderlies who require help in supporting their bodies. Patient recliners provide comfort and ergonomic support for patients during medical procedures or recovery. They feature fold-out foot rests, adjustable backrests, built-in tables, and optional safety features like bed rails. The growing geriatric population prone to disabilities and diseases is increasing the demand for patient recliners worldwide.

The global Patient Recliners Market is estimated to be valued at US$ 10.3 Bn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The rising geriatric population is one of the key trends driving the growth of the patient recliners market. According to the United Nations, the global population aged 60 years and older is growing at a rate of 3% every year and is expected to double by 2050. With age, incidence of injuries and mobility issues increase which necessitate the need for assistance devices like patient recliners. Patient recliners enable elders and disabled patients to rest comfortably under medical supervision and assistance. Leading manufacturers are focused on launching innovative patient recliners catering to the unique needs of the growing elderly demographic. This is expected to further accelerate the demand for patient recliners during the forecast period.

Segment Analysis

The global patient recliners market is dominated by the manual lifting segment which accounts for nearly 60% of the total market share. Manual lifting patient recliners are economical and can be easily transported from one place to another within hospitals and nursing homes. This allows caregivers to conveniently move patients without using any electrical equipment. Manual recliners are therefore preferred in budget constrained healthcare facilities across developing regions.

Key Takeaways

The global patient recliners market is expected to witness high growth over the forecast period of 2023 to 2030 supported by increasing elderly population worldwide and growing need for comfortable medical seating solutions. The global Patient Recliners Market is estimated to be valued at US$ 10.3 Bn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030

Regional analysis

The North America region currently dominates the global patient recliners market with over 35% share, led by the United States. High healthcare spending, developed healthcare infrastructure and presence of leading manufacturers have aided market growth in the region. However, Asia Pacific is expected to witness the fastest growth during the forecast period owing to rising medical tourism, expanding healthcare infrastructure and increasing investments by international players in countries such as China and India.

Key players

Key players operating in the patient recliners market are Medline Industries, LP., Krueger International (KI), Herman Miller, Inc., Gendron, Inc., Malvestio Spa, Stryker Corporation, Narula Udyog India Private Limited, Recliners India Private Ltd, Champion Chair, SaikangMedical, SeniorCare.com, and Jiangsu Yongfa Medical Equipment Technology Co., Ltd. Growing adoption of technologically advanced powered recliners is prompting established players to focus on new product launches and strategic collaborations to strengthen their market presence.

GMP Protein (E. coli) Contract Manufacturing Market in Focus: Collaborative Biomanufacturing Impact

 

Market Overview:

The GMP Protein (E. coli) Contract Manufacturing Market involves production of recombinant therapeutic proteins through fermentation of genetically engineered Escherichia coli (E. coli) cells. Manufacturers offer development and production services to biopharmaceutical clients from pre-clinical to commercial stage.

The global GMP Protein (E. coli) Contract Manufacturing Market is estimated to be valued at US$ 685.8 Mn in 2023 and is expected to exhibit a CAGR of 9.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Growing demand for affordable biologics: Biologics have revolutionized treatment of various chronic diseases. However, high costs limit patient access. This is driving demand for biosimilars and affordable biologics produced through contract manufacturing. Various organizations are outsourcing drug substance manufacturing to contract manufacturers that can offer cost savings up to 30-50% compared to in-house production.
Rapid scale-up capabilities: Leading contract manufacturers are making significant investments in single-use technologies and modular facilities to achieve rapid production scale-up within timelines demanded by biopharma companies. This is important to quickly meet anticipated commercial demand and get products to market faster.

Segment Analysis
The global GMP protein (E. coli) contract manufacturing market is dominated by the recombinant protein production segment. This segment held over 50% of the market share in 2023 owing to the growing applications of recombinant proteins in the development of therapeutics and diagnostics. Within recombinant protein production, monoclonal antibodies emerged as the highest revenue generating sub-segment. Monoclonal antibodies find widespread use in treating various indications such as cancer, inflammatory disorders, and infectious diseases.

Key Takeaways
The global GMP protein (E. coli) contract manufacturing market size was valued at US$ 685.8 Mn in 2023 and is expected to grow at a CAGR of 9.7% over the forecast period. North America currently dominates the market, accounting for over 35% share due to rising R&D investments by biopharmaceutical players in the region. However, Asia Pacific is poised to witness the fastest growth owing to improving manufacturing facilities and low-cost operations.

Some of the key players operating in the GMP protein (E. coli) contract manufacturing market are Merck & Co., Inc., Thermo Fisher Scientific Inc., Abcam plc, GenScript, Biomay AG, SOL GROUP, Proteintech Group, Inc., Nordmark Pharma GmbH, Sino Biological, Inc., Abnova Corporation, Eurofins Scientific, Arcline Investment Management LP, Abgenex, Xpress Biologics, Avid Bioservices Inc, Bio-Techne, Northway Biotech, Aldevron, Institut Mérieux, PerkinElmer Inc., Creative BioMart, Profacgen, ProBioGen AG, 53Biologics, Leadgene Biomedical, Inc., Ajinomoto Bio-Pharma, FUJIFILM Diosynth Biotechnologies, Avioq, Inc, Biovian Oy, KBI Biopharma, GTP Bioways, QIAGEN, Suzhou Novoprotein Technology Co., Ltd., ACROBiosystems, Kactus, F. Hoffmann-La Roche Ltd., and Enzo Life Sciences, Inc.